Results 11 to 20 of about 11,617 (148)

Lentiviral delivered aflibercept OXB-203 for treatment of neovascular AMD

Molecular Therapy: Methods & Clinical Development, 2023
Neovascular age-related macular degeneration (nAMD) is a leading cause of blindness in the aging population, with vascular endothelial growth factor (VEGF) playing a key role. Treatment with recombinant anti-VEGFs is the current standard of care; however,
Sharifah Iqball, Daniel K. Beck, Gayathri Devarajan, Cheen P. Khoo, Deirdre M. O’Connor, Scott Ellis, Efrain Guzman, Kyriacos A. Mitrophanous, Yatish Lad   +8 more
doaj   +1 more source

Aflibercept clearance through the drainage system in a rat model

International Journal of Retina and Vitreous, 2021
Background As intravitreal anti-VEGF injections became the mainstay of treatment for many retinal diseases, the cause of a secondary sustained elevated intraocular pressure is still unclear.
Yariv Keshet, Orly Gal-Or, Michal Schaap Fogler, Karin Mimouni, Meydan Ben Ishai, Dov Weinberger, Assaf Dotan   +6 more
doaj   +1 more source

pH of anti-VEGF agents in the human vitreous: low impact of very different formulations

International Journal of Retina and Vitreous, 2017
Background The aim of the study was to measure pH changes of the human vitreous caused by the intravitreal drugs bevacizumab, ranibizumab, aflibercept, and ziv-aflibercept.
Bianka Sobolewska, Peter Heiduschka, Karl-Ulrich Bartz-Schmidt, Focke Ziemssen   +3 more
doaj   +1 more source

Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer [PDF]

Farmacia Hospitalaria, 2014
Objectives: To estimate the incremental cost per life-year gained (LYG) of aflibercept in combination with FOLFIRI as second-line treatment in metastatic colorectal cancer (mCRC) patients previously treated with oxaliplatin.
M.ª Echave, C. Pericay, C. Frías, A. Abad, M.ª J. Lamas, I. Oyagüez, M. Rubio, M. Rubio, E. Giménez, S. Naoshy, F. Joulain   +10 more
doaj   +1 more source

Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding

International Journal of Retina and Vitreous, 2018
Purpose To investigate the binding affinity, stability, and sterility of aflibercept and ziv-aflibercept to vascular endothelial growth factor (Holash et al. in Proc Natl Acad Sci USA 99(17):11393–11398, 2002.
Julia de Lima Farah, Ronaldo Sano, Ieda Maria Longo Maugéri, Daniela Teixeira, Mayari Eika Ishimura, Gabriela Martins, Lycia M. J. Mimica, Cely Barreto da Silva, Carsten H. Meyer, João Rafael de Oliveira Dias, Gabriel Costa de Andrade, Michel Eid Farah   +11 more
doaj   +1 more source

Clinical Response To Switch From Ranibizumab To Aflibercept In Wet Age-Related Macular Degeneration

Delhi Journal of Ophthalmology, 2021
Introduction: To assess whether switching from Ranibizumab to Aflibercept conferred benefit in visual acuity (VA) and central macular thickness (CMT) in patients with wet age-related macular degeneration (AMD).
Bhagya Weerasinghe, Chandni Gupta, Yasmin Levene, Jai Shankar   +3 more
doaj   +1 more source

Analysis of Aflibercept Expression in NHPs following Intravitreal Administration of ADVM-022, a Potential Gene Therapy for nAMD

Molecular Therapy: Methods & Clinical Development, 2020
Several standard-of-care therapies for the treatment of retinal disease, including aflibercept, inhibit vascular endothelial growth factor (VEGFA). The main shortcoming of these therapies is potential undertreatment due to a lack of compliance resulting ...
Szilárd Kiss, Ruslan Grishanin, Aivan Nguyen, Romeo Rosario, Judith S. Greengard, Julio Nieves, Claire M. Gelfman, Mehdi Gasmi   +7 more
doaj   +1 more source

12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept

Indian Journal of Ophthalmology
Purpose: To investigate the 12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration (nAMD) in eyes previously treated with aflibercept.
Wajiha J Kheir, Mahdi Hassoun, Rola N Hamam, Ziad Fayez Bashshur   +3 more
doaj   +1 more source

Efficacy and safety of aflibercept in in vitro and in vivo models of retinoblastoma

Journal of Experimental & Clinical Cancer Research, 2016
Background To evaluate the inhibitory effects of aflibercept on the growth and subretinal invasion of retinoblastoma. Methods Xenotransplantation and orthotopic mouse models were created by injecting Y-79 cells subcutaneously and intravitreally ...
Dong Yoon Kim, Jeong A Choi, Jae-Young Koh, Young Hee Yoon   +3 more
doaj   +1 more source

Prime editing in neuropsychiatric disorders: From mutation‐specific target selection to clinical translation

Neuroprotection, EarlyView.
Abstract Prime editing, a novel clustered regularly interspaced short palindromic repeats (CRISPR)‐based technology, fuses a reverse transcriptase (RT) to an engineered CRISPR‐associated protein 9 (Cas9) and uses a prime editing guide RNA (pegRNA)‐encoded template.
Tianshan Ji, Yuan Zhang, Jinyi Zhao, Yiping Lu, Chengkun Wang   +4 more
wiley   +1 more source